The effect of Lactobacillus brevis KB290 against irritable bowel syndrome: a placebo-controlled double-blind crossover trial

BioPsychoSocial Medicine

Katsumi Murakami⁴  Chizu Habukawa³  Yukihiro Nobuta²  Naohiko Moriguchi⁴  Tsukasa Takemura¹ 

[1] Department of Pediatrics, Kinki University Faculty of Medicine, 377-2 ,Onohigashi, Osakasayama-shi, Osaka 589-8511, Japan

[2] Probiotics Research Group, Nature-Wellness research Department, Research Institute, KAGOME Co., LTD. 17 Nishitomiyama, Nasushiobara, Tochigi 329-2762, Japan

[3] Department of Pediatrics, Minami Wakayama Medical Center, 27-1 Takinai-machi, Tanabe-shi, Wakayama 646-0015, Japan

[4] Department of Pediatrics, Kinki University Sakai Hospital, 2-7-1 Harayamadai, Minami-ku, Sakai, Osaka 590-0132, Japan

关键词: Probiotic;    Lactobacillus brevis KB290;    Irritable bowel syndrome;   

Others  :  1082371
DOI  :  10.1186/1751-0759-6-16

 received in 2012-04-10, accepted in 2012-07-08,  发布年份 2012

【 摘 要 】

Background

Irritable bowel syndrome (IBS) is a functional disorder of the digestive tract that causes chronic abdominal symptoms. We evaluated the effects of Lactobacillus brevis KB290 (KB290), which has been demonstrated to be effective at improving bowel movements and the composition of intestinal microflora, on IBS symptoms.

Methods

We performed a placebo control double-blind cross matched trial. Thirty-five males and females (aged 6 years and above) who had been diagnosed with IBS according to the Rome III criteria were divided into 2 groups, and after a 4-week pre-trial observation period, they were administered test capsules containing KB290 or placebo for 4 weeks (consumption period I). Then, the capsule administration was suspended for 4 weeks in both groups (washout period), before the opposite capsules were administered for a further 4 weeks (consumption period II). Fecal samples were collected on the first day of the pre-consumption observation period, the last day of consumption period I, the last day of the washout period, and the last day of consumption period II. In addition, the subjects’ IBS symptoms and quality of life (QOL) and any adverse events that they experienced were evaluated.

Results

No significant difference in IBS symptoms was noted among the various periods. However, the mean QOL scores were improved during the test capsule consumption.

The frequencies of watery and mushy feces were significantly lower in the test capsule consumption period than during the pre-consumption observation period, and the frequency of abdominal pain was significantly reduced in the test capsule consumption period compared with the other periods.

The frequency of the genus Bifidobacterium was significantly higher, and that of the genus Clostridium was significantly lower, after the test capsule consumption than after the placebo consumption. The frequencies of the genera Lactobacillus, Bacteroides, and Enterococcus were also investigated, but no differences in their frequencies were detected between the placebo and test capsule consumption periods.

Conclusions

Probiotics, the safety of which has been established, are used widely in various foods and can now be purchased readily. The results of the present study suggest that KB290 is useful for early intervention in IBS.

【 授权许可】

   
2012 Murakami et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC: Functional bowel disorders. Gastroenterology 2006, 130(5):1480-1491.
• [2]Naliboff BD, Munakata J, Fullerton S, Gracely RH, Kodner A, Harraf F, Mayer EA: Evidence for two distinct perceptual alterations in irritable bowel syndrome. Gut 1997, 41(4):505-512.
• [3]Pimentel M, Chow EJ, Lin HC: Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am J Gastroenterol 2000, 95(12):3503-3506.
• [4]Spiller RC: Postinfectious irritable bowel syndrome. Gastroenterology 2003, 124(6):1662-1671.
• [5]Aragon G, Graham DB, Borum M, Doman DB: Probiotic therapy for Irritable Bowel Syndrome. Gastroenterology & Hepatology 2010, 6(1):39-44.
• [6]Bixquert Jimenez M: Treatment of irritable bowel syndrome with probiotics. An etiopathogenic approach at last? Rev Esp Enferm Dig 2009, 101(8):553-564.
• [7]Lee BJ, Bak YT: Irritable bowel syndrome, gut microbiota and probiotics. J Neurogastroenterol Motil 2011, 17(3):252-266.
• [8]Whorwell PJ, Altringer L, Morel J, Bond Y, Charbonneau D, O’Mahony L, Kiely B, Shanahan F, Quigley EM: Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am J Gastroenterol 2006, 101(7):1581-1590.
• [9]Lui Y, Fatheree NY, Mangalat N, Rhoads JM: Human-derived probiotic Lactobacillus reuteri strains differentially reduce intestinal inflammation. Am J Physiol Gastrointest Liver Physiol 2010, 299:G1087-G1096.
• [10]Nobuta Y, Inoue T, Suzuki S, Arakawa C, Yakabe T, Ogawa M, Yajima N: The efficacy and the safety of Lactobacillus brevis KB290 as a human probiotics. Inter J Probio Prebio 2009, 4(4):263-270.
• [11]Fukao M, Tomita H, Yakabe T, Nomura T, Ike Y, Yajima N: Assessment of antibiotic resistance in probiotic strain Lactobacillus brevis KB290. J Food Prot 2009, 72(9):1923-1929.
• [12]Yakabe T, Takashima H, Kuwagata M, Fukao M, Kikuchi S, Yajima N: Teratogenicity and maternal effects of Lactobacillus brevis KB290 in rats and rabbits. Food Chem Toxicol 2011, 49(4):722-726.
• [13]Yakabe T, Moore EL, Yokota S, Sui H, Nobuta Y, Fukao M, Palmer H, Yajima N: Safety assessment of Lactobacillus brevis KB290 as a probiotic strain. Food Chem Toxicol 2009, 47(10):2450-2453. Epub 2009 Jul 5
• [14]Rome Foundation: Guidelines--Rome III Diagnostic Criteria for Functional Gastrointestinal Disorders. J Gastrointestin Liver Dis 2006, 15(3):307-312.
• [15]Nagashima K, Hisada T, Sato M, Mochizuki J: Application of new primer-enzyme combinations to terminal restriction fragment length polymorphism profiling of bacterial populations in human feces. Appl Environ Microbiol 2003, 69(2):1251-1262.
• [16]Hamanishi S, Sekine C, Chin G, Yamaue T, Kagaminori S: Research on health indicators and QOL of children measured by nutrition, exercise, and rest: QOL. Japanese version of COOP chart for infants. Shoni no Eiyo, Undo, Kyuyo kara mita Kenkodo Shihyo to QOL ni kansuru Kenkyu 2004, 47-50.
• [17]Madden JA, Hunter JO: A review of the role of the gut microflora in irritable bowel syndrome and the effects of probiotics. Br J Nutr 2002, 88(Suppl 1):S67-S72.
• [18]Mitsuoka T: Cho-nai kin no sekai. Soubunsya 1984, 1980:15-20.
• [19]Midtvedt AC, Carlstedt-Duke B, Midtvedt T: Establishment of a mucin-degrading intestinal microflora during the first two years of human life. J Pediatr Gastroenterol Nutr 1994, 18(3):321-326.
• [20]Hehemann JH, Correc G, Barbeyron T, Helbert W, Czjzek M, Michel G: Transfer of carbohydrate-active enzymes from marine bacteria to Japanese gut microbiota. Nature 2010, 464(7290):908-912.
• [21]Erwin G, Zoetendal Chad T, Collier Satoshi K, Roderick I, Mackie H, Rex G: Molecular Ecological Analysis of the Gastrointestinal Microbiota: A Review. J Nutr 2004, 134(2):465-472.
• [22]Handelsman J: Metagenomics: application of genomics to uncultured microorganisms. Microbiol Mol Biol Rev 2004, 68(4):669-685.
• [23]Tannock GW: Molecular methods for exploring the intestinal ecosystem. Br J Nutr 2002, 87(Suppl 2):S199-S201.
• [24]Apostolou E, Pelto L, Kirjavainen PV, Isolauri E, Salminen SJ, Gibson GR: Differences in the gut bacterial flora of healthy and milk-hypersensitive adults, as measured by fluorescence in situ hybridization. FEMS Immunol Med Microbiol 2001, 30(3):217-221.
• [25]Rousselon N, Delgenès JP, Godon JJ: A new real time PCR (TaqMan PCR) system for detection of the16S rDNA gene associated with fecal bacteria. J Microbiol Methods 2004, 59(1):15-22.
• [26]Diamond B, Huerta PT, Tracey K, Volpe BT: It takes guts to grow a brain: Increasing evidence of the important role of the intestinal microflora in neuro- and immune-modulatory functions during development and adulthood. BioEssays 2011, 33(8):588-591.
• [27]Cryan JF, O’Mahony SM: The microbiome-gut-brain axis: from bowel to behavior. Neurogastroenterol Motil 2011, 23(3):187-192.
• [28]Heijtz RD, Wang S, Anuar F, Qian Y, Björkholm B, Samuelsson A, Hibberd ML, Forssberg H, Pettersson S: Normal gut microbiota modulates brain development and behavior. Proc Natl Acad Sci U S A 2011, 108(7):3047-3052.
• [29]Bercik P, Denou E, Collins J, Jackson W, Lu J, Jury J, Deng Y, Blennerhassett P, Macri J, McCoy KD, Verdu EF, Collins SM: The intestinal microbiota affect central levels of brain-derived neurotropic factor and behavior in mice. Gastroenterology 2011, 141(2):599-609.
• [30]O’Mahony L, McCarthy J, Kelly P, Hurley G, Luo F, Chen K, O’Sullivan GC, Kiely B, Collins JK, Shanahan F, Quigley EM: Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 2005, 128(3):541-551.